Survival Characteristics in 566 patients Receiving ICD: Real-World Data From The Canberra Hospital Device (TCH-ICD) Registry

Survival data: In 566 consecutive patients with survival data, who had received ICD between January 2005- June 2019 (median follow-up 25 months), the all-cause mortality was 17.8%, cardiovascular deaths in 53.4%, heart failure in 35.6%, and arrhythmia-related in 17.8%. Mean time-to-death was 63645 months. All-cause mortality was 14.9% in primary prevention (1o) group, 20.9% in secondary prevention (2o) group, 16.8% in ischaemic cardiomyopathy (ICMP), 16.1% in nonischaemic cardiomyopathy (NICMP), and 32.3% in mixed CMP. Significant differences between survivors & non-survivors: higher age, comorbidity index, creatine level, coronary artery disease, NYHA symptom class, mixed CMP; lower LV ejection fraction (LVEF) at implant & during follow-up. Nonsurvivors, when compared to survivors, received significantly higher therapies, 50% vs 31%, and shocks, 37% vs 21%. Incidence of death was significantly more in patients with therapies, 25.5% vs 13.5%, and appropriate shocks, 80.6% vs 57.8%. Significant predictors of mortality based on Cox regression model revealed age, kidney disease, malignancy, creatine level, baseline LVEF and device therapy. Kaplan-Meier curves revealed significantly earlier time-to-death for patients with mixed CMP & those receiving appropriate shocks. Conclusions: We have reported survival characteristics from 2,955 person-years of follow-up data from a real-world registry. 2o prevention group and mixed CMP had higher allcause mortality amongst all sub-groups. Comorbidities, LVEF and age at implant determine all-cause mortality irrespective of the type of cardiomyopathy. Shocks delivered from device and change in LVEF also contribute significantly to mortality.